Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

What went right: Why is HIV a treatable infection?

Nature Medicine volume 3, pages 714–717 (1997)Cite this article

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wurtman, R.J. & Bettiker, R.L. The slowing of treatment discovery. Nature Med. 1, 1122–1125 (1995).

    Article  CAS  Google Scholar 

  2. Centers for Disease Control and Prevention Update: Trends in AIDS incidence,deaths and prevalence — United States, 1966. Morb. Mortal. Wkly. Rep. 46, 165–73 (1997).

  3. Barre-Sinoussi, G. et al. T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome. Science 220, 868–861 (1983).

    Article  CAS  Google Scholar 

  4. Popovic, M., Sarngadharan, M.G., Read, E. & Gallo, R.C., tection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497–500 (1984).

    Article  CAS  Google Scholar 

  5. Kohl, N.E. et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Nat. Acad. Sci. USA 85, 4686–4690 (1988).

    Article  CAS  Google Scholar 

  6. Toh, J., Ono, M., Saigo, K. & Miyata, T. Retroviral protease-like sequence in the yeast transposon Tyl. Nature 315, 691 (1985).

    Article  CAS  Google Scholar 

  7. Mansky, L. & Temin, H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from the fidelity of purified reverse transcriptase. J. Virology 69, 5087–5094 (1995).

    CAS  PubMed  Google Scholar 

  8. Collier, A.C. et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New Engl. J. Med 334, 1011–1017 (1996).

    Article  CAS  Google Scholar 

  9. Mellors, J.W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167–1170 (1996).

    Article  CAS  Google Scholar 

  10. Kramer, L. Reports from the holocaust. St. Martin's Press, New York, (1994).

    Google Scholar 

  11. Shultz, R. And the band played on. St. Martin's Press, New York, (1982).

    Google Scholar 

  12. Young, J.J. AIDS and the FDA. In: AIDS and the public debate. C. Hannaway, V.A.Harden, and J. Parascandola, eds., pp 47–66, IOS Press, Washington, D.C. (1985).

    Google Scholar 

  13. Shulman, S.R. and Brown, J.S. The food and drug administration's early access and fast track approval initiatives: How have they worked? Food and Drug Law Journal 50, 503–531 (1995).

    CAS  PubMed  Google Scholar 

  14. DiMasi, J.A. A new look at United States drug development and approval times. Am J Therapeutics 3, 1–11 (1996).

    Article  Google Scholar 

Download references

Authors
  1. Richard J
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wurtman M D
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

J, R., M D, W. What went right: Why is HIV a treatable infection?. Nat Med 3, 714–717 (1997). https://doi.org/10.1038/nm0797-714

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0797-714

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing